SCHEMBL21112946

SCHEMBL21112946

CC(=O)O[C@@H]1O[C@H](C(=O)N2CCN(C/C=C/c3ccccc3)CC2)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 1/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.48
▸ KDM4E B2RXH2 3/20 0.48
▸ LMNA P02545 4/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ USP2 O75604 1/20 0.47
▸ ALDH1A1 P00352 7/20 0.47
▸ MAPT P10636 3/20 0.47
▸ MAPK1 P28482 1/20 0.46
▸ THRB P10828 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ HTT P42858 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ CHRM3 P20309 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20873353 0.80 OGA (0.33) MEN1KMT2ATHRB
SCHEMBL21148794 0.79 SIGMAR1 (0.47) KDM4ELMNAMEN1KMT2AUSP2
SCHEMBL20873345 0.79 TFPI2 (0.47) CYP2C19SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL20873321 0.77 HSD11B1 (0.41) KDM4ELMNAKMT2ATHRB
SCHEMBL24137920 0.76 ALDH1A1 (0.51) SMN1; SMN2KDM4ELMNAMEN1KMT2A
SCHEMBL20873259 0.75 HRH3 (0.38) ALDH1A1MAPTTHRBGAAL3MBTL1
SCHEMBL21112925 0.74 GAA (0.47) SMN1; SMN2KDM4ELMNAMEN1KMT2A
SCHEMBL21113001 0.74 CYP2C19 (0.55) CYP2C19SMN1; SMN2KDM4ELMNAMEN1
SCHEMBL21112924 0.73 HRH2 (0.35) KDM4EUSP2ALDH1A1THRBCHRM3
SCHEMBL21112937 0.73 PPP5C (0.38) LMNATHRBTSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2021-12-30 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 CYP2C19 2610/4885SMN1; SMN2 4049/4885KDM4E 4398/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 CYP2C19 2610/4885SMN1; SMN2 4049/4885KDM4E 4398/4885
US-20210401946-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 CYP2C19 2610/4885SMN1; SMN2 4049/4885KDM4E 4398/4885
US-20210401947-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 CYP2C19 2610/4885SMN1; SMN2 4049/4885KDM4E 4398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback